AVBP

Business Context and Reporting Period

Arrivent Biopharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on identifying, licensing, and globalizing biopharma innovations, primarily for oncology. The company's lead candidate is firmonertinib, a third-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC). This Form 10-Q covers the quarterly period ended June 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss for the six months ended June 30, 2025, increased to $95.8 million from $39.3 million in the same period in 2024. This represents a $56.5 million increase.
• R&D Expense Surge: R&D expenses rose significantly to $89.0 million (six months 2025) from $38.8 million (six months 2024). The primary driver was a $40.0 million upfront payment made in January 2025 to Lepu Biopharma for the exclusive license of ARR-217, an antibody drug conjugate for gastrointestinal cancers.
• Discovery Program Costs: Expenditures on discovery-stage programs increased by $38.0 million year-over-year, largely attributable to the Lepu transaction.
• Financing Activity: During the six months ended June 30, 2025, the company raised approximately $81.9 million through its "at-the-market" (ATM) equity program. In contrast, the prior year period included proceeds from the initial public offering (IPO).
• Investment Income: Interest and investment income decreased to $4.6 million (six months 2025) from $7.1 million (six months 2024) due to decreased invested balances.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes that existing cash, cash equivalents, and marketable securities ($254.5 million as of June 30, 2025), combined with net proceeds of $81.1 million from a public offering closed on July 3, 2025, are sufficient to fund operations for at least 12 months from the filing date.
• Clinical Progress:
  • Firmonertinib: Positive interim data was announced in June 2025 for the FURTHER trial (PACC mutations), showing a 16.0-month median progression-free survival. The company plans to initiate the ALPACCA Phase 3 study in the second half of 2025.
  • ARR-217: The company secured rights to this ADC candidate via the Lepu agreement and paid a $1 million milestone in Q2 2025.
• Financing Facilities: The company has a $75 million term loan facility with Silicon Valley Bank (undrawn as of June 30, 2025) and an ATM program with approximately $164.9 million remaining capacity.
• Risks:
  • Capital Requirements: The company expects to incur significant losses as it advances clinical trials and has no approved products. Future funding is required to sustain operations beyond the 12-month horizon.
  • Development Risk: Success depends on clinical trial outcomes, regulatory approvals, and the ability to commercialize products, all of which are uncertain.
  • Market Volatility: Geopolitical tensions and capital market volatility could impact the ability to raise additional capital.

Investor Verification Checklist

• Lepu Transaction Impact: Verify the specific terms and future milestone obligations associated with the $40 million upfront payment to Lepu Biopharma for ARR-217.
• Cash Burn Rate: Confirm the projected cash burn rate given the significant increase in R&D spend and the timeline for the next capital raise.
• Clinical Trial Enrollment: Monitor enrollment progress for the upcoming ALPACCA Phase 3 trial and the FURVENT Phase 3 trial.
• ATM Program Usage: Track the utilization of the remaining $164.9 million ATM capacity and the impact of the July 2025 offering on share count and dilution.
• Debt Facility Conditions: Review the specific conditions required to draw down the $75 million Silicon Valley Bank credit facility.